Novo Nordisk has terminated its partnership with telehealth company Hims & Hers Health, accusing it of deceptively marketing ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Novo Nordisk (NVO) said in a statement on Monday that it would halt its collaboration with Hims & Hers Health (HIMS) and that ...

Amanda Bynes revealed that she plans to use the injectable drug Ozempic to help achieve her weight loss goals, noting she ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says.

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish ...

Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia.

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...